Purpose Prostate cancer is a major cause of cancer mortality in American males. Once prostate cancer has metastasized, there is currently no curative therapy available.
morphological changes, increases in S-phase and sub-G1 cell fractions, an elevation of caspase 3/7 activity, DNA fragmentation and apoptotic cells. NSC increased the levels of apoptotic proteins, Bax and Bak, and induced a release of cytochrome c from mitochondria to cytosol in DU-145 cells. Co-administration of Z-VAD-FMK, a pan-caspase inhibitor, blocked NSC-induced caspase 3/7 activity and cell apoptosis without aVecting NSC-induced cell cycle arrest. In contrast, co-administration of a PKC inhibitor, rottlerin, had no signiWcant eVect on NSC induction of caspase activity, and slightly potentiated NSC-induced cell death. Furthermore, like camptothecin, a mutation of topoisomerase 1 that prevents the binding of camptothecin to the enzyme completely abolished the NSC eVect in DU-145 cells. Conclusion The data obtained suggest that NSC is able to decrease cell growth, induce cell apoptosis and cause growth arrest in prostatic tumor cells, which may involve an interaction with topoisomerase 1 and an activation of mitochondrial apoptotic pathway. 
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Introduction
Prostate cancer is a leading cause of cancer mortality in American and Western European males [1] [2] [3] . Once prostate cancer has metastasized, it is ultimately fatal for there is currently no curative treatment available [4, 5] . The major treatment, androgen deprivation therapy, is often only palliative and rarely curative. The tumor cells ultimately develop resistance to anti-androgen therapy and continue to metastasize. Chemotherapy has been used for the treatment of prostate cancer for years. However, the chemotherapeutic regimens used previously have little or no impact on the disease process [5, 6] . Recent eVorts in chemotherapy with new agents and new combinatorial regimens have made signiWcant progress, and improved the median survival in advanced prostate cancer patients [7, 8] .
Camptothecins, as a promising new class of anticancer drugs, have advanced to the forefront of therapeutic and developmental chemotherapy, when either used alone or in combination. The demonstration of topoisomerase 1 (Top1) as the molecular target of camptothecins and the development of water-soluble derivatives with less side eVects have translated this class of drugs into agents in the treatment of cancer [9] [10] [11] [12] . Two water-soluble camptothecin analogs have been approved by The Food and Drug Administration for clinical application: topotecan, as a second-line therapy for ovarian cancer or small-cell lung cancer, and irinotecan, for the treatment of colorectal carcinoma refractory to 5-Xuorouracil or as initial therapy in combination with 5-Xurouracil for the treatment of metastatic colorectal cancer [11] . NSC606985 (NSC), a highly water-soluble camptothecin analog, has rarely been studied for its anticancer activity. Recent studies indicate that NSC can target other cellular molecular targets in addition to Top1 to display its anticancer activity. For example, NSC has been shown to inhibit HIF-1 induced gene transcription in transfection assays and hypoxia-induced VEGF gene expression in tumor cells [13] .
We have recently shown that NSC produces a novel and diVerential eVect in leukemic cells. In NB4 and U937 leukemic cells, NSC induces a proteolytic activation of PKC , resulting in a PKC -mediated caspase-dependent and a caspase-independent cell death; whereas, in K562 leukemic cells, it inhibits cell growth without activation of PKC and cell apoptosis [14] . In the current study, we investigated the eVect and potential mechanisms of NSC in prostate cancer cells. The results obtained suggest that the anti-tumor activity of NSC in prostate cancer cells involves the interaction with Top1 and an activation of the mitochondrial apoptotic pathway. It warrants further investigation as a potential therapeutic agent for the treatment of hormone-refractory prostate cancer. 50 units/ml of penicillin and 50 g/ml of streptomycin. Cells were maintained in a 5% CO 2 -95% air humidiWed atmosphere at 37°C, and cultured in phenol-red free medium with 5% stripped FBS (Gemini Bio-Products, Calabasas, CA, USA) 24 h before experiments as described [15] .
Materials and methods
Reagents
Cell proliferation and caspase 3/7 activity assays For the determination of viable cell numbers and caspase 3/7 activity, prostate cancer cells were plated in 96-well plates at a density of approximately 40%, and treated with various drug regimens as indicated in the experiment 24 h after plating. The number of viable cells was determined using CellTiter AQueous One Solution Cell Proliferation Assay kit, and the caspase 3/7 activity, a common pathway in cell apoptosis, was determined using the Caspase-Glo 3/7 Assay kit from Promega (Madison, WI, USA) following the manufacturer's instruction. At the end of treatment, cells were collected, and analyzed for nuclear DNA content distribution and cell apoptosis. For DNA content analysis, cells were washed with phosphate buVered saline (PBS) and Wxed with 70% ethanol for 1 h. The cells were centrifuged at 300g for 5 min, pellet washed twice with cold PBS, suspended in 500 l PBS and incubated with 5 l RNase (20 g/ml Wnal concentration) at 37°C for 30 min. The cells were then chilled over ice for 10 min and stained with propidium iodide (PI, 50 g/ml Wnal concentration) for 1 h, and analyzed by Xow cytometry with a FACScan (Becton Dickinson, Germany). For Xow cytometric analysis of cell apoptosis, cells were stained with Annexin V in combination with PI using the Annexin V-FITC apoptosis detection kit I from BD Pharmingen (San Diego, CA, USA) according to the manufacturer's instruction.
Determination of DNA fragmentation
The fragmented DNA was visualized by DNA-agarose gel electrophoresis followed by ethidium bromide staining as described [16] . BrieXy, NSC treated and untreated cells were harvested and incubated in a lysis buVer [50 mmol/l Tris-HCl (pH 8.0), 20 mmol/l ethylenediamine tetra-acetic acid (EDTA), 10 mmol/l NaCl, 1% sodium dodecylsulfate (SDS)] for 20 min on ice. The samples were then centrifuged and treated with DNase-free RNase A and proteinase K. Following phenol and chloroform extraction, DNA was precipitated by ethanol and dissolved in 1£ Tris-EDTA buVer. DNA fragmentation was analyzed in a 2% agarose gel, visualized by ethidium bromide staining and photographed under ultraviolet light.
Western blot analysis
Western blot was carried out following standard method as previously described with minor modiWcations [17] . BrieXy, cells were harvested and total cellular proteins were extracted using a lyses buVer (62.5 mM Tris-HCl pH 6.8, 100 mM dithiothreitol (DTT), 2% SDS, 10% glycerol). The protein concentrations were determined using the Bio-Rad Protein Assay following the manufacturer's instruction (Bio-Rad, Hercules, CA, USA). Equal amounts of proteins were fractionated on a 15% SDS-PAGE, and transferred to PVDF membrane (Amersham Pharmacia Biotech, Piscataway, NJ, USA). The blots were blocked with TBST buVer [500 mM NaCl, 20 mM Tris-HCl (pH 7.4), and 0.1% Tween 20] containing 5% nonfat dry milk and then incubated with speciWc primary antibody in TBST buVer containing 5% nonfat dry milk (Bio-Rad Laboratories, Hercules, CA, USA) overnight at 4°C. Following secondary antibody incubation, the signal was visualized using the SuperSignal West Pico Chemiluminescent kit (Pierce Biotechnology Inc., Rockford, IL, USA), and exposed to Kodak X-Max Wlm. -Tubulin was used as an internal control by incubating a speciWc antibody against -tubulin with the same membrane following stripped oV.
Analysis of cytochrome c release
The detection of cytochrome c release from mitochondria to cytosol was performed as previously described with minor modiWcations [18] . BrieXy, harvested cells were pelleted by centrifugation and resuspended in 5£ volumes of BuVer A [20 mM HEPES, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EDTA, 1 mM ethylene glycol bis( -aminoethyl ether)-N,N,NЈ,NЈ-tetraacetic acide (EGTA), 1 mM DTT, 0.1 mM phenylmethylsulfonyl Xuoride (PMSF), and complete protease inhibitors] supplemented with 250 mM sucrose. The samples were incubated on ice for 30 min, and then homogenized in a TeXon homogenizer. The samples were fractionated by three sequential centrifugations of 1,000g, 10,000g, and 20,000g. The pellet obtained at 10,000g was considered as the "mitochondrial" fraction and the supernatant at 20,000g as the cytosol fraction. The fractionated proteins were analyzed by Western blot in a 15% SDS-PAGE as described above.
Statistics
The data are presented as mean § SEM. One-way analysis of variance (ANOVA) following post hoc StudentNewman-Keuls test was used to determine the diVerence among multiple groups. A P value less than 0.05 was considered statistically signiWcant.
Results
NSC decreased viable cell numbers in multiple prostate cancer cells
To determine whether NSC is eVective in inhibiting cell growth, the number of viable cells was determined in multiple prostate cancer cell lines after treatment with NSC. As shown in Fig. 1 , treatment with NSC produced a time-and dose-dependent decrease in viable cell numbers in multiple prostate cancer cell lines, including hormone-sensitive LNCaP cells, and hormone-independent DU-145 and PC-3 cells. At a dose of 50 nM, NSC caused a more than 50% reduction of viable cell numbers after 72 h treatment compared to the original cell numbers in DU-145 cells (Fig. 1a) . Similar NSC eVects were observed in PC-3 cells (Fig. 1b) . However, LNCaP cells were less sensitive to NSC, and the decrease in viability at 72 h was not so obvious when compared to the original cell number (Fig. 1c) . As a positive control, treatment with vinblastine (VBT), a cell mitotic inhibitor, at 0.1 g/ml concentration for 72 h signiWcantly decreased viable cell number in all prostate cancer cells ( Fig. 1c ; [15] ).
NSC induced cell apoptosis and cell cycle arrest
To determine whether NSC induced decreases in viable cell number is associated with cell apoptosis, the NSC eVect on apoptosis was analyzed in DU-145 and LNCaP cells. As shown in Fig. 2a-d , treatment with NSC in DU-145 cells produced dose-and time-dependent morphological changes that were characteristics of apoptosis such as chromatin condensation and nuclear fragmentation with intact cell membrane. Analysis of nuclear DNA distribution using Xow cytometry showed that NSC induced a time-and dosedependent increase in hypoploid cells (sub-G1 cells). The fraction of sub-G1 cells, an important indication of apoptotic cells, was increased from 2.1% in control DU-145 cells to 3.0, 20.3 and 27.6% in cells treated with NSC (50 nM) for 24, 48 and 72 h, respectively. This NSC induction of sub-G1 cells was completely blocked by the concomitant administration of Z-VAD-FMK (20 M), a pan-caspase inhibitor [19] . The fraction of S-phase cells was increased from 18.41% in control DU-145 cells to 38.58, 34.14 and 36.27% in cells treated with NSC (50 nM) for 24, 48 and 72 h (see Fig. 2e-h (Fig. 3g-j) . In contrast, the addition of rottlerin (1 M) slightly potentiated the NSC induced apoptosis and cell death (Fig. 3k-l) . Actually, treatment with rottlerin alone also increased cell apoptosis and cell death in DU-145 cells. NSC induced cell apoptosis was further supported by demonstrating that NSC (50 nM) produced a time-dependent induction of DNA fragmentation (Fig. 3o) , a land marker of cell apoptosis. NSC produced a dose-and time-dependent induction of caspase activity As shown in Fig. 4 , treatment with NSC produced a timeand dose-dependent induction of caspase 3/7 activity in DU-145 cells. Treatment with NSC for 4 h did not alter the caspase 3/7 activity. However, the caspase 3/7 activity was signiWcantly increased at 24 h of NSC treatment at a dose of 50 nM, and further elevated after 48 h of treatment. This NSC-induced increase in caspase activity was completely blocked by the co-administration of Z-VAD-FMK (20 M), a pan-caspase inhibitor. Whereas, the addition of rottlerin, a PKC inhibitor, failed to inhibit the NSC action while it slightly potentiated the NSC-induced caspase activity at 1 M of rottlerin at 48 h. These changes in caspase activity were parallel to the changes in cell apoptosis as shown in Figs. 2 and 3 . As a positive control, cells treated with paclitaxel (100 nM), a microtubule-interacting agent that induces apoptosis via activation of caspases [20] , also showed a signiWcant increase in caspase 3/7 activity at 48 h of treatment, which was blocked by Z-VAD-FMK.
NSC treatment increased Bax and Bak levels and caused cytochrome c release from mitochondria to cytosol in DU-145 cells Treatment with NSC at 50 nM for 24 h in DU-145 cells produced a more than twofold induction of Bax and Bak, two pro-apoptotic factors related to the mitochondrial apoptotic pathway, which were not aVected by the co-administration of Z-VAD-FMK as shown in Fig. 5a and b, as they are in the upstream of caspase activation in the mitochondrial apoptotic pathway.
To determine whether cytochrome c was released from mitochondria into cytosol in NSC-treated cells, cytosolic and mitochondrial fractions of proteins were prepared from NSC-treated DU-145cells, and analyzed by Western blot. As shown in Fig. 5c , NSC induced a time-dependent accumulation of cytochrome c in the cytosol with a simultaneous reduction in the mitochondrion. Cox IV, an inner membrane molecule of mitochondria, used as a marker of mitochondrial fraction, was not detected in the cytosol. The NSC actions were blocked by a pan-caspase inhibitor, but not a speciWc PKC inhibitor in DU-145 cells As a previous study [14] indicates that NSC-induced apoptosis involves PKC activation in leukemic cells, the involvement of PKC in NSC-induced apoptosis and cell growth inhibition was tested in DU-145 cells using a speciWc PKC inhibitor, rottlerin [21] . As shown in Fig. 6 , rottlerin failed to modulate the NSC-induced decrease in viable cell numbers although rottlerin itself caused a dose-dependent inhibition of cell growth. Similarly, rottlerin did not block the NSCinduced caspase activity (Fig. 4) and slightly potentiated NSC-induced apoptosis (Fig. 3) . On the other hand, coadministration of Z-VAD-FMK, a pan-caspase inhibitor, with NSC signiWcantly rescued cell growth (Fig. 6) , as well as completely blocked the NSC-induced caspase 3/7 activity (Fig. 4) and cell apoptosis (Figs. 2, 3) . As a positive control, treatment with paciltaxel at 100 nM signiWcantly decreased the number of viable cells (Fig. 6 ) while induced the caspase activity (Fig. 4) , which were signiWcantly blocked by the coadministration of Z-VAD-FMK.
Top1 mutation abolished the NSC eVects
To determine whether the NSC-induced cell growth inhibition involves the interaction with Top1 in DU-145 cells, DU-145RC0.1 and DU-145RC1, two cell lines derived from DU-145 cells that are resistance to camptothecin due to a Top1 mutation that abolishes the binding of camptothecin to top1 [22] , were treated with various doses of NSC for 72 h. As shown in Fig. 7 , both NSC and camptothecin failed to decrease the numbers of viable cells in these Top1 mutated cells although they produced a dramatic eVect in the parental DU-145 cells. However, paclitaxel, a cytotoxic agent by acting on microtubules, was as eVective in the Top1 mutated DU-145RC0.1 cells as in the parental DU-145 cells.
Discussion
Camptothecins have become a rapidly growing family of anticancer agents with a wide-spectrum anticancer activity and impressive in vivo eYcacy as exempliWed by the two FDA-approved drugs: topotecan and irinotecan. In the present study, we have demonstrated that NSC, a rarely studied and water-soluble camptothecin analog, produced a doseand time-dependent inhibition of cell growth and promotion of cell apoptosis and cell cycle arrest in multiple prostate cancer cells as evidenced by the determination of viable cell numbers, examination of cell morphology, Xow cytometric analyses, detection of cytochrome c release from mitochondria to cytosol, and analyses of caspase activity and DNA fragmentation. Similar to our observation in leukemic cells [14] , NSC produced a cell diVerential eVect, i.e., in DU-145 cells, it caused dramatic cell apoptosis and Fig. 6 The NSC-induced decrease in viable cell number was blocked by Z-VAD-FMK, a pan-caspase inhibitor, but not rottlerin, a PKC inhibitor in DU-145 cells. DU-145 cells were treated with or without NSC (50 nM) for 72 h in the presence or absence of various doses of rottlerin or 20 M of Z-VAD-FMK, and the numbers of viable cells were determined as described in "Materials and methods". The data were presented as percent of vehicle control, and the values are the mean § SEM of 6-12 individual samples from two to four independent triplicate experiments. * P < 0.05 and ** P < 0.01 compared to vehicle control; ## P < 0.01 compared to 50 nM NSC treatment (Student-Newman-Keuls test). P-tax devotes paclitaxel (100 nM), FMK, Z-VAD-FMK and Rot, rottlerin growth arrest, while it mainly induced growth arrest in LNCaP cells. Although previous studies have shown that camptothecin and its analogs may interact with various molecular targets such as inhibition of HIF-1 induced gene transcription, hypoxia-induced VEGF gene expression [13, 23] , and activation of PKC [14] , our current study in DU-145 cells suggests that the primary target of NSC is Top1, resulting in DNA damage, and an activation of apoptotic pathway.
Top1 plays an essential role in cell metabolism and survival and it is a primary target of camptothecins [10, 12, 24] . The conventional role of human Top1 comprises of the relaxation of DNA supercoiling and relief of torsional strain during DNA processing, including replication, transcription and repair. Competothecin stabilizes the covalent top1-DNA cleavage complex by reversibly blocking top1-mediated DNA religation and free top1 release, and thus leaves the DNA with a protein-linked DNA single-strand break, which triggers DNA damage, cytotoxic lesions and cell apoptosis as well as cell cycle arrest in the G2/M boundary [10, 12, 25] . Consistent with camptothecin actions, treatment with NSC in DU-145 cells produced a dose-and time-dependent cell apoptosis accompany with a cell cycle arrest. By using camptothecin-resistant cell lines, DU-145RC0.1 and DU-145RC1, which have a mutated top1 to prevent the binding of camptothecin to the enzyme [22] , we have shown that the NSC as well as camptothecininduced decreases in viable cell numbers were completely blocked by the mutation of top1. Taken together, these data suggest that similar to camptothecin, NSC-induced cell apoptosis and inhibition of cell growth is mediated primary through the interaction with top1, an activation of mitochondrial apoptotic pathway, and an induction of cell cycle arrest. Whether NSC possesses distinct actions from other camptothecin analogs in prostate cancer cells remains to be determined. DNA damage-induced cell apoptosis generally involves the intrinsic apoptotic pathway, in which the mitochondrion plays a central role [10, 26, 27] . The involvement of mitochondria in NSC-induced apoptosis is supported by the demonstration of NSC induction of cytochrome c release from mitochondria to cytosol (Fig. 5c) . This is also supported by a previous study showing that NSC causes a loss of mitochondrial transmembrane potential [14] . The observation that NSC-induced Bax and Bak, two pro-apoptotic proteins that can create pores in mitochondrial membranes and promote cytochrome c release [28, 29] , provides additional evidence to support the involvement of mitochondria in NSC actions. The release of cytochrome c from mitochondria into cytosol triggers the oligomerization of Apaf-1, resulting in an activation of procaspase 9, caspase-3 and/or caspase-7, and eventually cell apoptosis. The dependency of caspase activation in NSCinduced cell apoptosis is supported by the demonstration that NSC-induced caspase 3/7 activity and cell apoptosis were blocked by the concomitant administration of Z-VAD-FMK, a speciWc pan-caspase inhibitor.
Previous studies in leukemic cells have shown that NSCinduced cell apoptosis and growth inhibition involves the activation of PKC activity-an event upstream to mitochondrial trans-membrane potential loss and caspase-3 activation since rottlerin, a speciWc PKC inhibitor, completely blocked NSC-induced mitochondrial trans-membrane potential loss and caspase-3 activation [14] . However, our current demonstration that concomitant administration of rottlerin, a speciWc PKC inhibitor [21] failed to inhibit NSC-induced cell apoptosis (Fig. 3) , modulate caspase activation (Fig. 4) and growth inhibition (Fig. 6) , suggests that PKC activation is not necessary for NSC-induced cell apoptosis and growth inhibition in DU-145 cells. Furthermore, treatment with rottlerin alone in DU-145 cells produced a dose-dependent decrease in viable cell numbers (Fig. 6) , and an increase in cell death (Fig. 3k) , a phenomenon observed in other cells such as chronic lymphocytic leukemia cells [30] , suggesting that the endogenous PKC activity may be necessary for cell survival and/or proliferation. Taken together, these data indicate that NSC actions involve diVerential molecular targets in diVerent cells, and further support the concept that the eVects of PKC are highly relevant to cellular context, which may be mediated via distinct pathways [31] .
In summary, our current study demonstrates that NSC, a camptothecin analog promoted cell apoptosis and inhibited cell growth in multiple prostate cancer cells. Like camptothecin, the NSC-induced cell apoptosis and growth inhibition may involve the interaction with top1, cell cycle arrest and the activation of mitochondrial apoptotic pathway. These data suggest that NSC is a potential agent for the treatment of prostate cancer, especially hormone-independent prostate cancer and warrants further investigations as NSC possesses antitumor activity, and is superior to topotecan and irinotecan both in vitro leukemic cell cultures and in vivo leukemic animal models [32] .
